For the three months ending July 31, 2023, AGILENT TECHNOLOGIES ($NYSE:A) recorded total revenue of USD 1672.0 million, a decrease of 2.7% year-on-year. Net income was reported to be USD 111.0 million, a decrease of 66.3% in comparison to the same period from the previous year.
Analysis – Agilent Technologies Stock Fair Value Calculation
Analyzing AGILENT TECHNOLOGIES‘ fundamentals, GoodWhale has provided an insightful and thorough analysis. Our proprietary Valuation Line estimates the intrinsic value of AGILENT TECHNOLOGIES share to be around $151.4. Comparing this to the current market price of $125.6, we can conclude that the stock is undervalued by 17.1%. Therefore, AGILENT TECHNOLOGIES stock is currently trading at a fair price. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Agilent Technologies. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Agilent Technologies. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Agilent Technologies. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Agilent Technologies are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company has a strong presence in the market and competes with Qiagen NV, Thermo Fisher Scientific Inc, Illumina Inc, and other companies. Agilent Technologies Inc. is committed to providing innovative products and services that meet the needs of customers and enable them to achieve their research goals.
Qiagen is a Dutch company that provides molecular diagnostic solutions, including kits and instruments for sample preparation and real-time PCR. The company has a market cap of 9.99B as of 2022 and a ROE of 13.07%.
– Thermo Fisher Scientific Inc ($NYSE:TMO)
Thermo Fisher Scientific Inc is a biotechnology company that manufactures and sells scientific instruments, reagents, and laboratory products. The company has a market capitalization of 201.37 billion as of 2022 and a return on equity of 12.43%. Thermo Fisher Scientific is a global leader in serving science, with revenues of more than $30 billion and a workforce of more than 70,000 employees. The company’s mission is to enable its customers to make the world healthier, cleaner, and safer.
Illumina Inc. is an American company headquartered in San Diego, California. It is a provider of sequencing and array-based solutions for genetic analysis. The company has a market cap of $36.65 billion as of 2022 and a return on equity of 0.28%. Illumina’s products are used by academic and commercial researchers in a variety of fields, including cancer, infectious disease, genetics, and more.
Agilent Technologies’ third quarter financial results for the period ending July 31, 2023 indicate a decrease in total revenue of 2.7% compared to the same period in the prior year. Net income suffered a more significant decline of 66.3%. Despite these figures, Agilent Technologies appears to be a sound investment opportunity based on its current position and past performance. The company is well established and has a strong financials with an excellent track record of consistent profitability.
Moreover, the company has a solid balance sheet and is well positioned to capitalize on favorable industry trends. Investors should consider the current market outlook and long-term growth potential before investing in Agilent Technologies.